PharmaFocus Today – Page 117 – media

Challenge hepatitis B Therapy “Everest”

2%, 80%, 24 times – three figures, hiding the password of China’s hepatitis B treatment drug research and development from weak to strong. Breaking through the 2% survival rate of startups in the industry with a pioneering spirit; Breaking through foreign technology blockade, independent research and development innovation, with a market share of over 80% for individual products; Persisting in doing the ‘difficult but right thing’, single product revenue has increased 24 times in 8 years… Recently, a reporter from Shanghai Securities News visited Xiamen Tebao Bioengineering Co., Ltd. to record the growth story of this Chinese biopharmaceutical enterprise’s’ breakthrough ‘,’ jointing ‘, and’ heading ‘. Innovative drug research and development ‘nine deaths for a lifetime’ Xiamen Biomedical Port, with the sound of waves, inspires people to strive forward. 30 years ago, this was still a sugarcane field, but now it has become one of the national level industrial clusters ...
- Source: drugdu
- 389
- February 12, 2025
Cracking the problem of sky high prices of anti-cancer drugs, new progress has been made in universal CAR-T, and the stock price of Keji Pharmaceutical has surged by 197% in half a year

Keji Pharmaceutical (02171. HK) has made new progress in its universal CAR-T products. On February 10th, Keji Pharmaceutical announced that the first enrolled patient of the universal BCMA CAR-T developed based on the THANK-u Plus platform had a strict sense of complete response (sCR) and minimal residual disease (MRD) negative efficacy evaluation at the 28th day visit. According to its introduction, the patient is a recurrent/refractory multiple myeloma IgA – λ type (R-ISS stage II), who has received first-line combination therapy and autologous hematopoietic stem cell transplantation in the past. After the last treatment, the disease progressed and was included in the clinical trial. This CAR-T product is intended for the treatment of relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractory plasma cell leukemia (R/R PCL). Affected by this news, on February 10th, the stock price of Keji Pharmaceutical rose by more than 12% at one point after opening, and finally ...
- Source: drugdu
- 491
- February 12, 2025
The Wealth Creation Myth of GLP-1 Market Exceeding $50 Billion

GLP-1 drugs have lived up to expectations and delivered an unexpected result in 2024, with a global market size of 51.8 billion US dollars. The two giant single products, Simeglutide and Tilpotide, continue to soar, with strong growth beyond imagination. Starting from 2022, GLP-1 drugs began to show explosive potential, with a market size exceeding the $20 billion threshold that year, followed by nearly $35 billion in revenue in 2023, and now breaking through $50 billion in one fell swoop, achieving a triple leap in three years and aiming to reach $60 billion by 2025. In terms of market share, both Novo Nordisk and Eli Lilly shine brightly, with the former holding a market share of around 58% and the latter occupying the remaining share. The sales of products developed by other GLP-1 players have declined. From a numerical perspective alone, the GLP-1 market is already comparable to the PD ...
- Source: drugdu
- 329
- February 12, 2025
Minimally invasive surgery dark horse changes coach

On February 7th, Intuitive Fosun officially announced that Dr. Liu Qijun has joined the company and taken over as CEO, stationed in the Shanghai office. Since November 15, 2024, when Pan Xiaofeng, the former CEO of Intuitive Fosun, officially retired, this news has caused a “huge uproar” in the medical equipment industry. Since then, it has been uncertain who will replace the new CEO. Finally, three months later, Intuitive Fosun has welcomed a new leader. Newly appointed CEO takes office Robot surgery is hailed as the “third technological revolution” in the field of surgery, marking a new milestone in the development of modern surgery. Although China started relatively late in the field of robotic surgery, the huge demand has driven the rapid development of this technology. In this technological revolution, Intuitive Surgery quickly gained a foothold in the global operating room market with its revolutionary product – the da Vinci ...
- Source: drugdu
- 380
- February 12, 2025
Scan the code to know the “past and present” of the drug. The medical insurance drug consumables traceability information query function is online

February 10 (Reporter Xu Penghang) The reporter learned from the National Medical Insurance Bureau on the 10th that the “Medical Insurance Drug Consumables Traceability Information Query” function of the National Medical Insurance Service Platform APP was officially launched recently. By scanning the drug traceability code on the medicine box, drug buyers can obtain detailed drug sales information and understand the “past and present” of the drug. At present, nearly 33,000 people use this function to query drug sales information every day. The drug traceability code is the only “electronic ID card” for each box of drugs. The traceability code of a box of drugs should only have a record of being scanned and sold once. If it appears repeatedly, there is a possibility of counterfeit drugs, reflux drugs or drugs being sold in exchange. According to reports, after drug buyers register and log in to the National Medical Insurance Service ...
- Source: drugdu
- 232
- February 12, 2025
Jinhe Bio (002688.SZ) ranks second in the number of blue ear vaccine batches issued, and large vaccine products continue to emerge

According to statistics from Xinzhupai, the number of blue ear vaccine batches issued in 2024 will total 412 million, which is basically the same as in 2023. Boehringer ranks first with more than 60 million batches issued. Jinhe Youben, a subsidiary of Jinhe Bio, which has become popular with blue ear inactivated vaccines, has ranked second for two consecutive years, with nearly 40 million batches issued in 2024. Public information shows that Jinhe Bio is based on the animal health industry, and has entered the veterinary biological products business field through external mergers and acquisitions, and has a full layout of the veterinary vaccine sector. There are currently 16 products on the market, and more than 20 products under research and application, with broad development space and strong potential. Among them, the blue ear inactivated vaccine Youlanbao® and blue ear chimeric vaccine Youlantai® launched by Jinhe Bio’s subsidiary Jinhe Youben ...
- Source: drugdu
- 275
- February 12, 2025
Another domestic herpes zoster vaccine has been applied for listing, and the vaccination market for middle-aged and elderly people is still to be opened

The domestic herpes zoster vaccine market is about to enter the “Three Kingdoms Killing”. On the evening of February 9, Green Bamboo Bio (02480.HK) announced that its application for listing of the recombinant herpes zoster vaccine LZ901 was accepted by the National Medical Products Administration. If successfully listed, this vaccine will become the third herpes zoster vaccine listed in China. Currently, there are two herpes zoster vaccines on the market, one is a domestic vaccine, the manufacturer is Baike Bio; the other is an imported vaccine, the manufacturer is GlaxoSmithKline. Herpes zoster is an infectious skin disease caused by the reactivation of the varicella-zoster virus that has been latent in the dorsal root ganglia or cranial ganglia of the spinal cord for a long time. As people age, their physiological metabolic and immune functions gradually decline, and the risk of contracting infectious diseases such as herpes zoster increases. Vaccination with ...
- Source: drugdu
- 298
- February 12, 2025
The rise of Digene Pharmaceuticals

Recently, Wu Qing, Chairman of the China Securities Regulatory Commission, stated in a signed article entitled “Strive to Create a New Situation of High-Quality Development of the Capital Market” published in the magazine “Qiushi”: “Support the development of new quality productivity, support the issuance and listing of high-quality non-profit technology-based enterprises, and develop diversified equity financing.” With the gradual implementation of this policy concept, the capital market has ushered in new development opportunities. On February 7, Dizhe Pharmaceuticals issued an announcement stating that the targeted issuance plan of the Science and Technology Innovation Board has been registered by the China Securities Regulatory Commission, and it is expected to raise no more than 1.85 billion yuan. At the same time, this is also the first non-profit enterprise refinancing plan to be registered on the Shanghai Stock Exchange since the release of the “Eight Measures on Deepening the Reform of the Science ...
- Source: drugdu
- 289
- February 12, 2025
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: I. Accurate Market Insights: AI as Your Detective (1) Quickly Identify Customers and Markets: Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. (2) Monitor Competitors in Real-Time: With DeepSeek, ...
- Source: drugdu
- 487
- February 11, 2025
AI DeepSeek Drugdu Pharma Trade
One medical device enters the priority approval green channel

On February 6th, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 2 of 2025), and the products of Aoran Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Aoran Biotechnology”) – Mycobacterium tuberculosis complex and rifampicin resistant nucleic acid detection kit (PCR fluorescence probe method) entered the priority approval green channel. It is worth mentioning that this product belongs to the category of medical devices listed in the National Science and Technology Major Special Project, and is also the 7th IVD related product to enter the priority channel this year. Domestic pioneering technology At present, tuberculosis is still one of the most widely spread and lethal infectious diseases in the world. China is the second country with high burden of tuberculosis in the world. The World Health Organization has proposed the action goal of ending the prevalence ...
- Source: drugdu
- 226
- February 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.